SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Wire to Wire Daily Stock Picking -- Ignore unavailable to you. Want to Upgrade?


To: Jeffrey L. Henken who wrote (807)6/28/1999 4:40:00 AM
From: Henrik  Read Replies (1) | Respond to of 3514
 
PGLAF - Henrik - Float ? - bid $3 5/16 - ask $ 3 3/4 - News attached

Stock jumped 20% on Australian Stock Exchange (ASX) on Monday 28th.
---------------------------------------------------------------------

PROGEN INDUSTRIES LIMITED. 1999-06-28 ASX-SIGNAL-G
HOMEX - Brisbane
+++++++++++++++++++++++++
INTERIM US FDA APPROVAL POSITIVE AND PROGEN RECEIVES APPROVAL FOR
CANCER TRIALS FROM ROYAL MELBOURNE HOSPITAL ETHICS COMMITTEE

Brisbane, Australia Monday 28th June, 1999 Progen Industries Ltd (ASX
Code: PGL; NASDAQ Code: PGLAF) is pleased to announce that the Royal
Melbourne Hospital Ethics Committee has approved Progen's Phase I/Ib
PI-88 anti-cancer trial application, subject to final US FDA
approval.

Progen has received Friday, Washington time, June 25th, formal FDA
clearance for trial pharmacology/toxicology/microbiology safety
review. A final response regarding manufacturing chemistry is
expected this week.

Contact details:
Mr S Chang, Chairman Tel: 61 7 3273 9100
Mr A Scott, Managing Director Tel: 61 7 3273 9100
Mr S Anderson, Six Sigma Tel: 1 415 776 6499
Carolyn McCann, Phillips Group Tel: 61 7 3230 5000
==================================================================
also: biz.yahoo.com